Man sues Novo Nordisk alleging blindness linked to GLP-1 drug
A Georgia father of four who used a GLP-1 medication for diabetes has filed a lawsuit claiming the drug caused sudden vision loss, joining other plaintiffs alleging the same side effect.
A Georgia state highway worker and father of four has filed a lawsuit against Novo Nordisk, alleging that a GLP-1 medication he used for diabetes triggered a sudden loss of vision. Gillen said he first noticed a visual disturbance on a Saturday morning, which progressed to complete blindness within days, leaving him reliant on a walking stick.
Doctors have described the condition as non-arteritic anterior ischemic optic neuropathy (NAION), an eye stroke sometimes referred to in media reports as “Ozempic blindness.” Gillen’s case adds to a growing number of lawsuits alleging a possible link between GLP-1 weight-loss drugs and NAION.
“If I would’ve read that there was a possibility I could lose my vision, I would’ve never taken this drug,” said Diane Wirth, another plaintiff who filed a suit after becoming legally blind in one eye shortly after starting a GLP-1 injection.
Novo Nordisk responded that its internal study found no increased risk of NAION among users of its GLP-1 products. The lawsuits are scheduled to be heard before a federal judge in Philadelphia, where plaintiffs argue the company failed to adequately disclose the rare but serious side effect.
The legal proceedings may take several years, and the cases are being monitored by local news outlets.